Drugs / EBV-AST
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07450391 | Jun 2025 → Jun 2027 expected | Epstein-Barr virus-associated lymphoproliferative disorder, lymphoma | Daihong Liu | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-AST | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07450391 ↗ |
| Action | Deplete | “EBV-AST cells are expected to recognize and eliminate EBV-infected or EBV-antigen-expressing target cells” NCT07450391 ↗ |
| Modality | Cell therapy | “EBV-AST is a cellular immunotherapy consisting of EBV antigen-specific cytotoxic T lymphocytes generated by ex vivo stimulation and expansion of T cells using antigen...” NCT07450391 ↗ |
| Route | Intravenous | “EBV-AST is administered by intravenous infusion every 2 weeks” NCT07450391 ↗ |